Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Entresto Risk Sharing Could Equate To 8.6% Discount, ICER Says; Is Express Scripts Interested?

This article was originally published in The Pink Sheet Daily

Executive Summary

Cost effectiveness report on Novartis’ new heart failure drug includes a hypothetical risk-sharing payment model using hospitalization or death as patient endpoints; Express Scripts exec notes outcomes-based contracts have been problematic but hints at potential for Entresto.

Advertisement

Related Content

Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register